LeMaitre Vascular Inc (LMAT) Shares Sold by Citadel Advisors LLC

Share on StockTwits

Citadel Advisors LLC lessened its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 26.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 117,374 shares of the medical instruments supplier’s stock after selling 42,424 shares during the quarter. Citadel Advisors LLC owned 0.60% of LeMaitre Vascular worth $4,547,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of LMAT. Conestoga Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 15.4% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,607,000 shares of the medical instruments supplier’s stock valued at $62,255,000 after purchasing an additional 214,409 shares in the last quarter. Epoch Investment Partners Inc. boosted its holdings in shares of LeMaitre Vascular by 20.8% in the 2nd quarter. Epoch Investment Partners Inc. now owns 932,093 shares of the medical instruments supplier’s stock valued at $31,207,000 after purchasing an additional 160,754 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of LeMaitre Vascular by 4.9% in the 3rd quarter. BlackRock Inc. now owns 2,545,148 shares of the medical instruments supplier’s stock valued at $98,599,000 after purchasing an additional 119,694 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of LeMaitre Vascular by 14.4% in the 2nd quarter. Janus Henderson Group PLC now owns 691,670 shares of the medical instruments supplier’s stock valued at $23,157,000 after purchasing an additional 87,197 shares in the last quarter. Finally, Summit Creek Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 37.0% in the 3rd quarter. Summit Creek Advisors LLC now owns 292,814 shares of the medical instruments supplier’s stock valued at $11,344,000 after purchasing an additional 79,053 shares in the last quarter. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on LMAT shares. Roth Capital raised LeMaitre Vascular from a “neutral” rating to a “buy” rating and reduced their target price for the company from $39.00 to $34.00 in a report on Monday, October 8th. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, September 8th. ValuEngine cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, October 6th. Canaccord Genuity dropped their price target on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating for the company in a research note on Monday, October 8th. Finally, Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Monday, October 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. LeMaitre Vascular currently has a consensus rating of “Hold” and an average target price of $35.86.

Shares of LMAT opened at $25.64 on Friday. LeMaitre Vascular Inc has a 52 week low of $25.11 and a 52 week high of $41.28. The firm has a market capitalization of $520.88 million, a PE ratio of 29.81, a PEG ratio of 2.17 and a beta of 1.00.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.21. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. The company had revenue of $24.17 million during the quarter, compared to analysts’ expectations of $26.06 million. On average, sell-side analysts predict that LeMaitre Vascular Inc will post 1.02 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th were paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend was Monday, November 19th. LeMaitre Vascular’s payout ratio is 32.56%.

In other news, Director Michael H. Thomas sold 20,000 shares of the stock in a transaction on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total value of $558,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $558,600. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by BBNS and is owned by of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://baseballnewssource.com/2018/12/08/lemaitre-vascular-inc-lmat-shares-sold-by-citadel-advisors-llc/3064140.html.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Read More: What are earnings reports?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.